Phase 3 N=203 Monotherapy Study of MP-513 in Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Change From Baseline in HbA1c at Week 12 — 0.17; -0.62 Percent
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Incisional Vacuum Assisted Closure (IVAC) Device and Its Effect on Implanted Bone Morphogenic Protein (BMP-2)
Fractures, Closed
Primary: Presence of BMP-2 in Effluent Collected in IVAC Canister — 6; 11 participants — p==0.36
Phase 2 N=51 Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma
Non-Hodgkins Lymphoma
Primary: Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 81 percentage of patients
N/A N=45 Treating People With Post-Traumatic Stress Disorder With Cognitive Behavioral Therapy for Insomnia
Post-Traumatic Stress Disorder
Primary: Sleep Latency (SL) — 14.27; 44.31 minutes
Phase 3 N=14 Pantoprazole on Insulin Secretion in Diabetes
Type 2 Diabetes
Primary: First Phase of Insulin Secretion — 13.8; 15.9 µU/ml
N/A N=26 Memantine for Executive Dysfunction in Adults With ADHD: A Pilot Study
Attention Deficit Hyperactivity Disorder (ADHD) · Executive Function Deficits (EFD)
Primary: Percent Change in Global Executive Composite T-Score on the Behavior Rating Inventory of Executive Function-Adult (BRIEF-A) — -24; -21 percentage change from baseline…
Phase 2 N=29 Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery
Recurrent Adrenocortical Carcinoma · Stage III Adrenocortical Carcinoma · Stage IV Adrenocortical Carcinoma
Primary: The Proportion of Patients Who Achieve a Confirmed Objective Response to Treatment, Either Partial Response (PR) or Complete Response (CR) as Defined by Response…
Phase 2 N=43 Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL®) as a Booster in Adolescents
Pertussis · Tetanus · Diphtheria
Primary: Percentage of Participants With Seroprotection Against Diphtheria and Tetanus Antigens Following Vaccination With ADACEL® — 100; 100 Percentage of Participants
Phase 3 N=27 Sildenafil to Improve Exercise Capacity in People With Thalassemia and Pulmonary Hypertension
Thalassemia · Hypertension, Pulmonary
Primary: Change in Six-minute Walk Test (6MWT) Distance From Baseline to Week 12 Among Sildenafil Group — -1.38 meters — p=0.97
Phase 1 N=12 Bioequivalence of Orfadin Suspension Compared to Orfadin Capsules, and the Effect of Food on the Bioavailability of the Suspension
Healthy Volunteers
Primary: The Area Under the Serum Concentration Curve (AUC) During 72 Hours After Dose (AUC72h) During Fasting Conditions. — 403; 346 uM*h
Phase 2 N=40 Neo-Penotran Forte Vaginal Suppository for Vaginal Trichomoniasis
Trichomonas Vaginitis
Primary: Percentage of Participants Cured of Vaginal Trichmonas — 90; 90; 88 percentage of participants
N/A N=160 Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration
Neovascular Age-related Macular Degeneration
Primary: Vision — 0.16 logMAR
Phase 1 N=40 Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes
Type 2 Diabetes
Primary: Change From Baseline in Postprandial Area Under the Curve From Time 0 to 8 Hours (AUC[0-8]) for Active Glucagon-like Peptide-1 — 26.5; 31.6; 3.8; -2.3 pmol/L*hr — p=0.388
Phase 2 N=24 Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy
Vitrectomy
Primary: Percentage of Eyes With Total Macular Posterior Vitreous Detachment (PVD). — 50; 62.5 percentage of eyes — p=0.679
Phase 2 N=53 Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Recurrent Mantle Cell Lymphoma
Primary: Number of Participants With an Overall Response Defined as Complete Response and Partial Response — 21 participants